-
1
-
-
42449128875
-
Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002
-
Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control CCC 2008; 19:379-390.
-
(2008)
Cancer Causes Control CCC
, vol.19
, pp. 379-390
-
-
Yamamoto, J.F.1
Goodman, M.T.2
-
3
-
-
84874053507
-
The myth of the second remission of acute leukemia in the adult
-
Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood 2013; 121:1077-1082.
-
(2013)
Blood
, vol.121
, pp. 1077-1082
-
-
Forman, S.J.1
Rowe, J.M.2
-
5
-
-
84876095248
-
Acute myeloid leukemia in first remission: To choose transplantation or not?
-
Stone RM. Acute myeloid leukemia in first remission: To choose transplantation or not? J Clin Oncol Off J Am Soc Clin Oncol 2013; 31:1262-1266.
-
(2013)
J Clin Oncol off J Am Soc Clin Oncol
, vol.31
, pp. 1262-1266
-
-
Stone, R.M.1
-
7
-
-
3242754448
-
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity
-
Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5:738-743.
-
(2004)
Nat Immunol
, vol.5
, pp. 738-743
-
-
Hope, K.J.1
Jin, L.2
Dick, J.E.3
-
8
-
-
0033815950
-
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
-
Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14:1777-1784.
-
(2000)
Leukemia
, vol.14
, pp. 1777-1784
-
-
Jordan, C.T.1
Upchurch, D.2
Szilvassy, S.J.3
-
9
-
-
84904465235
-
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
-
Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 2014; 124:385-392.
-
(2014)
Blood
, vol.124
, pp. 385-392
-
-
Frankel, A.E.1
Woo, J.H.2
Ahn, C.3
-
10
-
-
0035662980
-
Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies
-
Muñoz L, Nomdedéu JF, López O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001; 86:1261-1269.
-
(2001)
Haematologica
, vol.86
, pp. 1261-1269
-
-
Muñoz, L.1
Nomdedéu, J.F.2
López, O.3
-
11
-
-
28844456971
-
Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia
-
Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106:4086-4092.
-
(2005)
Blood
, vol.106
, pp. 4086-4092
-
-
Taussig, D.C.1
Pearce, D.J.2
Simpson, C.3
-
12
-
-
0034119046
-
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
-
Frankel AE, McCubrey JA, Miller MS, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000; 14:576-585.
-
(2000)
Leukemia
, vol.14
, pp. 576-585
-
-
Frankel, A.E.1
McCubrey, J.A.2
Miller, M.S.3
-
13
-
-
0034886842
-
High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
-
Alexander RL, Ramage J, Kucera GL, et al. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res 2001; 25:875-881.
-
(2001)
Leuk Res
, vol.25
, pp. 875-881
-
-
Alexander, R.L.1
Ramage, J.2
Kucera, G.L.3
-
14
-
-
84932085600
-
A Phase 1 study of the safety, pharmacokinetics and antileukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
-
He SZ, Busfield S, Ritchie DS, et al. A Phase 1 study of the safety, pharmacokinetics and antileukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma 2015; 56:1406-1415.
-
(2015)
Leuk Lymphoma
, vol.56
, pp. 1406-1415
-
-
He, S.Z.1
Busfield, S.2
Ritchie, D.S.3
-
15
-
-
84899137486
-
Monoclonal antibody targeting of IL-3 receptor a with CSL362 effectively depletes CML progenitor and stem cells
-
Nievergall E, Ramshaw HS, Yong ASM, et al. Monoclonal antibody targeting of IL-3 receptor a with CSL362 effectively depletes CML progenitor and stem cells. Blood 2014; 123:1218-1228.
-
(2014)
Blood
, vol.123
, pp. 1218-1228
-
-
Nievergall, E.1
Ramshaw, H.S.2
Yong, A.S.M.3
-
16
-
-
84929943283
-
First-in man, phase 1 study of CSL362 (anti-IL3Ra/anti-CD123 monoclonal antibody) in patients with CD123 acute myeloid leukemia (AML) in CR at high risk for early relapse [abstract]
-
Smith B, Roboz G, Walter R, et al. First-in man, phase 1 study of CSL362 (anti-IL3Ra/anti-CD123 monoclonal antibody) in patients with CD123 acute myeloid leukemia (AML) in CR at high risk for early relapse [abstract]. Blood 2014; 124:120.
-
(2014)
Blood
, vol.124
, pp. 120
-
-
Smith, B.1
Roboz, G.2
Walter, R.3
-
17
-
-
84904460162
-
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
-
Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res 2014; 2:4.
-
(2014)
Biomark Res
, vol.2
, pp. 4
-
-
Testa, U.1
Pelosi, E.2
Frankel, A.3
-
18
-
-
84937399143
-
Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTS1)
-
Blood 2013
-
Hussaini MA, Ritchey J, Retting M, et al.: Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTs1) [abstract]. Proceedings of the 55th ASH annual meeting; 2013. Blood 2013; 122:360.
-
(2013)
Proceedings of the 55th ASH Annual Meeting
, vol.122
, pp. 360
-
-
Hussaini, M.A.1
Ritchey, J.2
Retting, M.3
-
19
-
-
84929956747
-
Immunotherapy with long-lived anti-CD123 - Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123 cells in monkeys: A potential therapy for acute myelogenous leukemia. Proceedings of the 56th ASH annual meeting
-
Chu S, Pong E, Chen H, et al. Immunotherapy with long-lived anti-CD123 - Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123 cells in monkeys: A potential therapy for acute myelogenous leukemia. Proceedings of the 56th ASH annual meeting. Blood 2014; 124:2316.
-
(2014)
Blood
, vol.124
, pp. 2316
-
-
Chu, S.1
Pong, E.2
Chen, H.3
-
20
-
-
77956535599
-
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
-
Jena B, Dotti G, Cooper LJN. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; 116:1035- 1044.
-
(2010)
Blood
, vol.116
, pp. 1035-1044
-
-
Jena, B.1
Dotti, G.2
Cooper, L.J.N.3
-
21
-
-
84877669593
-
The basic principles of chimeric antigen receptor design
-
Sadelain M, Brentjens R, Riviè re I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3:388-398.
-
(2013)
Cancer Discov
, vol.3
, pp. 388-398
-
-
Sadelain, M.1
Brentjens, R.2
Riviè, R.I.3
-
22
-
-
80051775476
-
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
-
Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95-73.
-
(2011)
Sci Transl Med
, vol.3
, pp. 73-95
-
-
Kalos, M.1
Levine, B.L.2
Porter, D.L.3
-
23
-
-
84860718270
-
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
-
Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4:132-53.
-
(2012)
Sci Transl Med
, vol.4
, pp. 53-132
-
-
Scholler, J.1
Brady, T.L.2
Binder-Scholl, G.3
-
24
-
-
84876005284
-
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
-
Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177-38.
-
(2013)
Sci Transl Med
, vol.5
, pp. 177-238
-
-
Brentjens, R.J.1
Davila, M.L.2
Riviere, I.3
-
25
-
-
84908073316
-
Chimeric antigen receptor T cells for sustained remissions in leukemia
-
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507- 1517.
-
(2014)
N Engl J Med
, vol.371
, pp. 1507-1517
-
-
Maude, S.L.1
Frey, N.2
Shaw, P.A.3
-
26
-
-
84923019006
-
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial
-
Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet Lond Engl 2015; 385:517-528.
-
(2015)
Lancet Lond Engl
, vol.385
, pp. 517-528
-
-
Lee, D.W.1
Kochenderfer, J.N.2
Stetler-Stevenson, M.3
-
27
-
-
84888226232
-
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
-
Mardiros A, Santos CD, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 2013; 122:3138-3148.
-
(2013)
Blood
, vol.122
, pp. 3138-3148
-
-
Mardiros, A.1
Santos, C.D.2
McDonald, T.3
-
28
-
-
84876163922
-
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
-
Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013; 161:389- 401.
-
(2013)
Br J Haematol
, vol.161
, pp. 389-401
-
-
Tettamanti, S.1
Marin, V.2
Pizzitola, I.3
-
29
-
-
84905714921
-
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
-
Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014; 28:1596-1605.
-
(2014)
Leukemia
, vol.28
, pp. 1596-1605
-
-
Pizzitola, I.1
Anjos-Afonso, F.2
Rouault-Pierre, K.3
-
30
-
-
84901703340
-
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
-
Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014; 123:2343-2354.
-
(2014)
Blood
, vol.123
, pp. 2343-2354
-
-
Gill, S.1
Tasian, S.K.2
Ruella, M.3
-
31
-
-
0032722187
-
Correlation between IL-3 receptor expression and growth potential of human CD34 hematopoietic cells from different tissues
-
Huang S, Chen Z, Yu JF, et al. Correlation between IL-3 receptor expression and growth potential of human CD34 hematopoietic cells from different tissues. Stem Cells Dayt Ohio 1999; 17:265-272.
-
(1999)
Stem Cells Dayt Ohio
, vol.17
, pp. 265-272
-
-
Huang, S.1
Chen, Z.2
Yu, J.F.3
-
32
-
-
79955517235
-
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
-
Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121:1822-1826.
-
(2011)
J Clin Invest
, vol.121
, pp. 1822-1826
-
-
Savoldo, B.1
Ramos, C.A.2
Liu, E.3
-
33
-
-
80051589534
-
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
-
Wang X, Chang W-C, Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011; 118:1255-1263.
-
(2011)
Blood
, vol.118
, pp. 1255-1263
-
-
Wang, X.1
Chang, W.-C.2
Wong, C.W.3
-
34
-
-
84879409907
-
Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: A focus on hematopoietic cell transplantation
-
Kharfan-Dabaja MA, Lazarus HM, Nishihori T, et al. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: A focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 2013; 19:1006-1012.
-
(2013)
Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant
, vol.19
, pp. 1006-1012
-
-
Kharfan-Dabaja, M.A.1
Lazarus, H.M.2
Nishihori, T.3
-
35
-
-
84874536909
-
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study
-
Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study. Haematologica 2013; 98:239-246.
-
(2013)
Haematologica
, vol.98
, pp. 239-246
-
-
Pagano, L.1
Valentini, C.G.2
Pulsoni, A.3
-
36
-
-
84896335556
-
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
-
Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6:224-25.
-
(2014)
Sci Transl Med
, vol.6
, pp. 224-225
-
-
Davila, M.L.1
Riviere, I.2
Wang, X.3
-
37
-
-
84920693049
-
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia
-
Wang Q, Wang Y, Lv H, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther J Am Soc Gene Ther 2015; 23:184- 191.
-
(2015)
Mol Ther J Am Soc Gene Ther
, vol.23
, pp. 184-191
-
-
Wang, Q.1
Wang, Y.2
Lv, H.3
|